Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Gains from Sales and Divestitures (2022 - 2025)

Historic Gains from Sales and Divestitures for Organogenesis Holdings (ORGO) over the last 4 years, with Q3 2025 value amounting to $1.6 million.

  • Organogenesis Holdings' Gains from Sales and Divestitures rose 1067.23% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 1067.23%. This contributed to the annual value of $1.4 million for FY2024, which is 17452.53% up from last year.
  • Per Organogenesis Holdings' latest filing, its Gains from Sales and Divestitures stood at $1.6 million for Q3 2025, which was up 1067.23% from $1.6 million recorded in Q2 2025.
  • In the past 5 years, Organogenesis Holdings' Gains from Sales and Divestitures ranged from a high of $1.6 million in Q3 2025 and a low of $239245.0 during Q2 2022
  • For the 4-year period, Organogenesis Holdings' Gains from Sales and Divestitures averaged around $937954.1, with its median value being $949694.0 (2023).
  • Per our database at Business Quant, Organogenesis Holdings' Gains from Sales and Divestitures skyrocketed by 23034.84% in 2024 and then soared by 1067.23% in 2025.
  • Organogenesis Holdings' Gains from Sales and Divestitures (Quarter) stood at $249106.0 in 2022, then skyrocketed by 109.81% to $522651.0 in 2023, then surged by 174.53% to $1.4 million in 2024, then grew by 10.38% to $1.6 million in 2025.
  • Its last three reported values are $1.6 million in Q3 2025, $1.6 million for Q2 2025, and $1.6 million during Q1 2025.